SCHEDULE 13D: Bayer Entities Disclose Nearly 20% Stake in Senti Biosciences Following Strategic Investment
Beneficial Ownership Disclosure
Bayer HealthCare LLC and Bayer US Holding LLC, along with their managers, have disclosed a combined 19.99% beneficial ownership stake in Senti Biosciences, Inc. following a strategic investment involving preferred stock conversion and warrant exercise.
Summary
- Bayer HealthCare LLC, Bayer US Holding LLC, Sebastian Guth, and Gurumurthy Ramamurthy (collectively, the "Reporting Persons") have filed a Schedule 13D, disclosing beneficial ownership of 6,142,848 shares of Senti Biosciences, Inc. Common Stock.
- This aggregate amount represents 19.99% of Senti Biosciences' outstanding Common Stock.
- The ownership stems from a Securities Purchase Agreement entered into on December 2, 2024, where Bayer HealthCare LLC purchased 2,222 shares of Series A Preferred Stock for approximately $5.5 million and a warrant to purchase 3,333,000 shares of Common Stock.
- On March 6, 2025, Senti Biosciences' stockholders approved the issuance of Common Stock upon conversion of the Series A and exercise of the Warrants.
- Following stockholder approval, on March 10, 2025, Senti Biosciences automatically converted each share of Series A Preferred Stock into 1,000 shares of Common Stock, resulting in Bayer HealthCare LLC owning 2,809,848 shares of Common Stock.
- Bayer HealthCare LLC also has the right to exercise its Warrant to purchase 3,333,000 Warrant Shares, but due to a 19.99% beneficial ownership limitation, only 2,980,148 of these Warrant Shares are currently exercisable.
- The source of funds for these purchases was available cash on hand.
- The Reporting Persons have entered into a Registration Rights Agreement, requiring Senti Biosciences to file a registration statement within 120 days of the closing date to register the resale of shares beneficially owned by the Holders, including those held by the Reporting Persons and shares issuable upon warrant exercise.
Sentiment
Score: 7
Explanation: The sentiment is positive as it reflects a significant strategic investment by a major entity (Bayer) into Senti Biosciences, indicating confidence and potential future collaboration. While there's a beneficial ownership limitation, the overall transaction is a positive validation for Senti Biosciences.
Positives
- Significant strategic investment by Bayer entities, indicating confidence in Senti Biosciences' future.
- Stockholder approval for the equity issuance facilitates the conversion of preferred stock and exercise of warrants, streamlining the investment structure.
- A Registration Rights Agreement is in place, which will allow the Reporting Persons to register their shares for resale, providing a clear path to liquidity for their investment.
Negatives
- A blocking provision in the Warrant terms limits Bayer HealthCare LLC's immediate exercise to maintain beneficial ownership below 19.99%, preventing full exercise of the 3,333,000 Warrant Shares at once.
Risks
- The document highlights a contractual limitation where Bayer HealthCare LLC cannot exercise its Warrant if it would result in beneficial ownership exceeding 19.99% of the Common Stock outstanding, although this percentage can be increased to 45.00% with 61 days' prior notice to the Issuer.
Future Outlook
The Reporting Persons currently have no present plans for extraordinary corporate transactions, changes in Senti Biosciences' board or management, capitalization, dividend policy, business structure, or delisting. However, they may, from time to time, purchase additional shares or sell existing shares in the open market or privately negotiated transactions, subject to market conditions.
Management Comments
- Priyal Patel, Treasurer of Bayer HealthCare LLC and Bayer US Holding LLC, certified the information in the statement as true, complete, and correct to the best of their knowledge and belief.
- Sebastian Guth and Gurumurthy Ramamurthy also certified the information in the statement as true, complete, and correct to the best of their knowledge and belief.
Industry Context
This filing represents a significant strategic investment by a major pharmaceutical and healthcare conglomerate (Bayer) into a biotechnology company (Senti Biosciences, Inc.). Such investments are common in the life sciences sector, where larger entities seek to gain exposure to innovative technologies or potential future therapies developed by smaller, specialized firms. It signals a potential partnership or strategic alignment, which can be a positive indicator for the smaller company within the competitive biotech landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Stockholder Approval | Senti Biosciences' stockholders approved the issuance of Common Stock upon conversion of Series A Preferred Stock and exercise of Warrants, as required by Nasdaq Listing Rule 5635. | 2025-03-06 | This approval enables the full execution of the investment terms, allowing the Series A Preferred Stock to convert and the Warrants to become exercisable, thereby facilitating the capital infusion and ownership structure changes. |
Related Party Transactions
- The investment by Bayer HealthCare LLC and Bayer US Holding LLC in Senti Biosciences, Inc. through the purchase of Series A Preferred Stock and Warrants, along with the associated Registration Rights Agreement, constitutes a significant transaction between the parties.
Stakeholder Impact
- Shareholders: The conversion of preferred stock and potential exercise of warrants will lead to an increase in the number of outstanding common shares, potentially causing dilution. However, the significant investment by Bayer could also be seen as a validation of Senti Biosciences' technology and strategy, potentially boosting investor confidence.
- Employees: A substantial investment from a major player like Bayer could provide financial stability and resources, potentially benefiting employees through continued operations and future growth opportunities.
- Creditors: The capital infusion from the investment could strengthen Senti Biosciences' balance sheet, potentially improving its creditworthiness.
Next Steps
- Senti Biosciences is obligated to file a registration statement under the Securities Act of 1933 within 120 days of the closing date (December 2, 2024) to register the resale of shares beneficially owned by the Holders, including the Reporting Persons.
- The Reporting Persons may, from time to time, purchase additional shares of Common Stock or sell all or a portion of their currently owned or hereafter acquired shares, subject to market conditions and other factors.
Key Dates
| Date | Description |
|---|---|
| 2024-12-02 | Securities Purchase Agreement and Registration Rights Agreement entered into by Reporting Persons and Senti Biosciences, Inc. |
| 2025-01-21 | Date as of which Senti Biosciences reported 4,829,457 shares of Common Stock outstanding in its Definitive Proxy Statement filed on January 27, 2025. |
| 2025-03-06 | Senti Biosciences' stockholders approved the issuance of Common Stock upon conversion of Series A Preferred Stock and exercise of Warrants. |
| 2025-03-10 | Date of event requiring the filing of this Schedule 13D; Senti Biosciences exercised its option to automatically convert Series A Preferred Stock into Common Stock. |
| 2025-03-17 | Joint Filing Agreement and Power of Attorney executed by the Reporting Persons. |
Keywords
Senti Biosciences, Bayer HealthCare, Bayer US Holding, Schedule 13D, Beneficial Ownership, Preferred Stock, Warrants, Equity Investment, Biotechnology, Pharmaceutical Investment, SEC Filing, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.